encora

From Complexity to Clarity

The Executive Playbook for AI in Life Sciences

Engineering the Cognitive Enterprise



Contents

Executive Summary
The Imperative for Cognitive Transformation

The CEO Snapshot:

Why This Matters Now

The Friction:
Drug development costs have hit **$2.3 billion per asset,** while R&D returns hover near the cost of capital (5.9%).

The Leakage:
The industry loses **$35 billion annually** to cold chain failures and **$800,000 per day** to clinical trial delays.

The Fix:
This is not about dashboards. It is about **Agentic AI**—autonomous workflows that compress discovery by 50% and automate regulatory compliance.

The Strategy:
Move from "random acts of digital" to a **Composable Enterprise**

The Life Sciences sector faces a fundamental paradox. We have unmatched scientific capabilities—genomic precision, cell, and gene therapies—yet our operational systems to implement these are inadequate. We're observing “Eroom’s Law” [80] (see Figure 1), where the cost of innovation roughly doubles every nine years. As therapies advance, demonstrating their added value becomes more difficult, and their delivery costs escalate exponentially.



Figure 1 Eroom’s Law

The signs of this stagnation are clear and require immediate attention from the C-suite. The average cost to develop a new drug has steadily increased, reaching about $2.3 billion in 2024—a figure that reflects not only scientific expenses but also the costs related to failure and inefficiency built into traditional workflows [1]. While the top 20 global pharmaceutical companies experienced a slight rebound in R&D returns to 5.9%, up from a low of 1.2% in 2022, this figure is still dangerously close to the cost of capital, indicating a business model that is fundamentally under pressure [2].

This financial pressure is further amplified by a more complex regulatory and commercial environment. Worldwide, hundreds of thousands of active clinical programs generate a constant flow of submissions, safety reports, and lifecycle updates [3]. For the 25 largest pharmaceutical companies, studies indicate roughly 50,000 post-approval changes each year [4], while regulatory intelligence vendors track thousands of global updates annually [5]. Collectively, these factors present an ongoing, multi-jurisdictional compliance challenge that manual teams can no longer manage efficiently.

Furthermore, the industry is undergoing a major shift in its commercial approach. We are moving toward a Direct-to-Patient (DTP) model where patients, guided by data, become the main decision-makers in their care journey. This shift requires Pharma to develop new skills in direct engagement while managing the complex issues of PHI and data privacy—an ability gap that traditional commercial structures are not well equipped to handle. At the same time, the commercial engine is struggling; HCPs are retreating behind digital barriers, with only about 50% of physicians now considered “accessible” to sales reps, down from nearly 80% a decade ago [6].

In this environment, Artificial Intelligence (AI) has transitioned from being a theoretical disruptor to an essential operational tool. We are witnessing a shift from “doing digital”—marked by isolated pilots and dashboards—to “being digital,” where intelligent AI workflows fundamentally reshape the value chain. From Generative AI (GenAI) that halves molecular discovery timelines [7] to autonomous supply chain agents that reduce the $35 billion annual loss from cold chain waste [44], AI offers the only practical way to break the linear relationship between cost and output.

Encora bridges the gap between these visionary AI possibilities and enterprise reality. As an orchestration and engineering partner with a Net Promoter Score of 82.4 [82]and a track record of delivering 55% faster product cycles [83], we specialize in the complex 'heavy lifting'—from GxP-compliant data fabrics to automated multi-omics pipelines—that turns AI potential into scalable, audit-ready performance.

Sector Landscape

This guide showcases the current potential of AI in Life Science organizations addressing specific sector challenges. It highlights impactful AI solutions across twelve KPA = Key Process Areas selected from the Life Science value chain (See Figure 2). We explore how leading organizations are already leveraging AI to solve urgent problems—such as the “patent cliff,” rising R&D costs, regulatory complexities, and patient adherence. Through real-world examples, we demonstrate how AI enhances operations and even fundamentally transforms them.

It moves beyond hype to focus on evidence-based applications, quantifying the “Problem,” “Solution,” and “The Strategic Value of AI” for each domain. It demonstrates how, by using a composable, agent-driven approach, Life Science organizations can shift from a reactive stance to a proactive, predictive leadership role.

The Life Science industry is at a pivotal point. As AI shifts from pilot projects to full-scale enterprise deployment, it presents a significant opportunity and a considerable risk.

The message for C-suite executives is clear - AI has moved from being a cutting-edge technology to an essential strategic tool. Early adopters are gaining significant benefits through cost savings, enhanced customer experiences, and greater agility in navigating regulatory challenges.



Industry leaders must make a critical decision - embrace AI now or risk falling behind.

Part I - Research & Development

KPA 1. R&D

The Challenge - The “Eroom's Law” of Diminishing Returns

The drug discovery phase is the industry's most high-risk gamble, marked by a steady decline in productivity known as “Eroom's Law” [80], which shows that the number of new drugs approved per billion US$ of R&D spend has roughly **halved every 9 years** from 1950 to 2010 [9]. The process of finding a single viable candidate involves screening millions of compounds, making it resource-intensive with a high rate of failure. The main challenges stem from three areas:

High Attrition Rates

The traditional high-throughput screening model often produces “hits” with poor developability profiles (e.g., toxicity, solubility issues) that are not identified until costly late-stage trials.

Data Curation Bottleneck

Researchers are overwhelmed by a flood of multi-omics data. Manually harmonizing diverse datasets - such as genomic sequences, histopathological images, proteomic structures, and clinical phenotypes - is a huge drain on productivity. It’s estimated that data scientists and biologists spend 60-80% of their time just cleaning and organizing data, instead of generating insights.

Slow DMTA Cycles

The DMTA[1] cycle has traditionally been slow. The industry average to reach the preclinical candidate stage has been around 42 months (3.5 years), which significantly limits the number of hypotheses a team can test within a single budget cycle [7].

The Solution - Generative Biology & Agentic Multi-Omics

The use of AI in discovery changes the approach from “screening” to “generation.” Instead of looking for a needle in a haystack, Generative AI creates the needle.

1. **Agentic Data Harmonization -** An “Omics Ingestion Agent” can automate the ingestion and standardization of complex biological data. Unlike manual curation, which can take weeks, this agent can harmonize different datasets in less than 48 hours, using ontologies to ensure semantic consistency and spot potential biases at the input stage. This key step turns the “data swamp” into a “data lake,” allowing downstream models to train on high-quality inputs [10].

2. **Generative Chemistry & Biology** - Utilizing Logic-driven LLMs[2] and geometric deep learning (e.g., AlphaFold integration), AI agents can design novel molecular structures de novo [11]. These agents optimize multiple conflicting parameters simultaneously-binding affinity, solubility, and metabolic stability-before a single compound is synthesized. This MPO[3] capability allows researchers to filter out molecules that are likely to fail due to poor physicochemical properties, long before they reach a wet lab.

3. **Target Identification via Knowledge Graphs** - AI algorithms can analyze extensive collections of scientific literature, patent databases, and real-world patient data to build dynamic knowledge graphs. These graphs uncover hidden relationships between genetic markers and disease pathways, helping identify new targets with a higher chance of clinical success.

[1]DMTA = Design-Make-Test-Analyze

[2]LLM = Large Language Model

[3]MPO = Mult-Parameter Optimization

The Strategic Value of AI - The Velocity of Innovation

The strategic impact of AI in discovery is measured in velocity and precision -

50%

Timeline Compression

Streamline the “Design-Make-Test” cycle by shifting failure in silico. By generating and optimizing candidates computationally instead of physically, teams can reduce the time to reach a preclinical candidate by 50% [7].

30%

Cost Efficiency

Multi-Parameter Optimization (MPO) models - Filter out likely toxic or insoluble compounds before synthesis. This reduces physical screening needs, lowers the cost per lead series by approximately 30%, and directs wet-lab efforts toward high-probability candidates [12].

Research Productivity

Omics Ingestion Agents free scientists from the “data janitor” role. Automating the cleaning and harmonization of complex datasets allows researchers to focus on hypothesis creation instead of managing spreadsheets.



KPA 2. Pre-Clinical Development

The Challenge - The Translation Gap and Ethical Cost

Reliability of Animal Models

There is a significant “translation gap” where successful animal studies fail to predict safety or efficacy in humans. Over 92% of drugs that enter clinical trials fail, often because animal toxicity and efficacy data do not translate to human physiology [13].

Ethical and Financial Burden

Preclinical testing requires substantial resources. A single monoclonal antibody program can need up to 100 primates for toxicology studies, raising serious ethical issues and increasing costs between $15 million and $100 million per asset [1].

Regulatory Conservatism

While regulators indicate openness to alternatives, the industry has traditionally relied heavily on in vivo animal testing to lower regulatory risks, which lengthens development timelines by years [14].

The Solution - In Silico Toxicology & Virtual Controls

AI promotes the use of NAMs[4] that lessen dependence on live animal testing. Although in silico modeling has been around for years, older methods were slow and had high false-positive rates. Modern Agentic AI greatly improves accuracy and speed.

Virtual Control Groups (VCGs)
Instead of recruiting new groups of animals for control arms in each study, AI agents can analyze large databases of historical control data to create “Virtual Control Groups.” This approach uses legacy data to set the baseline, immediately reducing the number of animals needed for a study by 25% [15]. This not only saves costs but also supports the “3Rs” (Replacement, Reduction, Refinement) of animal welfare.

Predictive Toxicology Agents
Machine learning models (e.g., deep neural networks) can predict specific toxicity endpoints, such as hepatotoxicity or cardiotoxicity, by analyzing chemical structures and gene expression signatures. These “Digital Toxicology Agents” can identify toxic liabilities months before a physical study concludes [15].

Organ-on-a-Chip Analysis
AI can analyze complex, high-dimensional data from human organ-on-a-chip systems, translating micro-physiological information into systemic human risk predictions that are more relevant than animal proxies.

Digital Twins of Animal Models
By creating digital twins of specific animal physiologies, AI can simulate the biological response to a molecule before a physical dose is ever administered. This enables researchers to model complex systemic interactions in silico, reducing the number of physical animals needed for dose-ranging studies.

The Strategic Value of AI - De-Risking the Clinic

Reduced Development Time

Predictive Toxicology Agents and Digital Twins help identify safety signals months earlier. This shifts safety assessment from a bottleneck to a parallel process, reducing preclinical timelines from over 3 years to less than 2 years [16]..

Massive Cost Savings

Virtual Control Groups (VCGs) directly reduce the need for net-new animal cohorts. By replacing live control arms with historical data models, companies can immediately save 25% on animal procurement and husbandry costs per study [15].

Regulatory Leadership

Validated In Silico Safety Evidence is becoming a valuable asset. Companies presenting robust, AI-generated safety data can negotiate reduced in vivo requirements, accelerating IND[5] approval [17].

[4]NAM - New Approach Methodology
[5]IND = Investigational New Drug

The Encora Edge

AI-driven discovery is only as fast as your data pipelines. We recently helped **a global pharmaceutical leader achieve a 75% faster time-to-market and 70% cost savings** by modernizing their legacy cloud infrastructure and streamlining CI/CD workflows. We don't just talk about discovery; we engineer the high-speed rails it runs on.

Part II - Clinical Development

KPA 3. Clinical Trials - Phase 1-3

The Challenge - Complexity, Delay, and Disconnected Operations

Clinical trials are the most costly and complex phase of development. The current approach is unsustainable, marked by overly bloated protocols, recruitment issues, and inefficient data handling.

76% **Protocol Design**

76% of trials need significant amendments, often caused by flawed design, which increases costs and delays. [18].

37% **Protocol Complexity**

The scientific demand for data has caused "protocol bloat." Between 2016 and 2021, the average number of endpoints in Phase 3 trials increased by 37%, and the total procedures grew by 42% [19]. This complexity places a huge burden on sites and patients, leading to higher dropout rates.

80% **Recruitment and Enrollment Crisis**

Patient recruitment and enrollment are the primary reasons for trial delays. 80% of clinical trials fail to reach their enrollment goals on time [20].

$800K **Cost of Delay**

The financial impact of these delays is significant. Each day of delay results in approximately $800,000 in lost or unrealized prescription drug sales and $40,000 in daily clinical trial costs [21].

36.3 **Data Latency**

Data cleaning is a reactive, manual process. It takes an average of 36.3 days from LPLV6 to DBL7, trapping critical trial results in a cycle of manual queries and reconciliation [22].

[6]LPLV = last patient, last visit

[7]DBL = Database Lock

The Solution - The AI-Enabled Smart Trial Ecosystem

1. **Protocol Navigator (Generative Protocol Design)** - A "Document Generation Agent" can analyze thousands of historical protocols, regulatory guidelines, and real-world data to draft optimized protocols. These agents can identify "non-core" procedures that add cost without scientific value, directly tackling "protocol bloat" by suggesting more efficient, patient-friendly designs. A "Simulation Agent" can build a "digital twin" of the trial to test eligibility criteria in silico before the trial starts, predicting screen failure rates and adjusting criteria to maximize enrollment. A "Compliance Agent" can automatically cross-check the protocol against ICH E6(R3) and FDA guidelines.

2. **Predictive Site Selection** - Instead of depending on optimistic feasibility questionnaires, AI can analyze actual site performance data to forecast which sites will recruit patients. This data-driven method can enhance site selection accuracy by 30-50% [23].

3. **Intelligent Recruitment & Enrollment"**- shifting recruitment from a passive "wait and see" approach to an active "find and engage" strategy.

   - **Recruitment (Find)** - An "Eligibility Parsing Agent" converts complex natural language protocol criteria into precise, machine-readable queries to scan unstructured EHR data, actively identifying patients that traditional methods miss.

   - **Enrollment (Engage)** - Once identified, "Enrollment Agents" automate the screening and onboarding process, answering patient queries 24/7 to prevent drop-offs during intake.

4. **Site Operations Standardization Agent -** Site performance is often unpredictable and depends on individual staff abilities. AI agents can assist site coordinators with standardized workflows and automated scheduling, improving underperforming sites to meet high standards of operation and helping to reduce variability in data quality and patient experience.

5. **Automated Data Cleaning -** a "Data Review Agent" can continuously monitor incoming trial data streams. They identify anomalies, outliers, and inconsistencies in real-time, not weeks later, enabling a shift to risk-based monitoring.

The Strategic Value of AI - Operational Velocity

10-15%

Accelerated Timelines

Eligibility Parsing Agents and Predictive Site Selection replace “wait and see” recruitment with targeted precision approaches. This proactive engagement method speeds up enrollment by 10-15%, potentially cutting 6 months from the critical timeline [23].

30%

Efficiency Gains

Automated Data Review Agents Enable “Risk-Based Monitoring” by cleaning data in real-time. This reduces the cycle time from LPLV to DBL by approximately 45%, lowering data management costs by over 30% [24].

76%

Protocol Precision

Protocol Navigators (Generative Design) simulate eligibility criteria before the trial begins. This minimizes the risk of costly protocol amendments—which affect 76% of trials—saving both the direct costs of amendments and the related operational delays [18].

$400M

Financial Impact

Accelerating a trial by 12 months can add $400 million in NPV to an asset portfolio [23].

2-3 Weeks

Reporting Speed

Case studies show that GenAI can cut the time needed to draft a CSR[9] from approximately 2-3 weeks (around 180 hours) to about 3-4 days (roughly 80 hours), speeding up the critical path to regulatory submission.



[8]NPV = Net Present Value

[9]CSR = Clinical Study Report

KPA 4. Regulatory Approval

The Challenge - The Submission Bottleneck and Compliance Risk

The Regulatory Approval phase, being the final obstacle before market entry, is marked by extensive documentation requirements and high stakes. The number of regulatory changes is overwhelming, and manual submission processes are susceptible to errors.

Volume of Regulatory Change
Regulatory intelligence teams must monitor thousands of sources worldwide. Across the globe, hundreds of thousands of active clinical programs produce a continuous flow of submissions, safety reports, and lifecycle updates [3]. Missing even a single update can jeopardize a submission strategy.

Drafting Bottlenecks
Creating submission dossiers (e.g., Module 2 summaries, CSRs) demands months of effort from highly skilled medical writers. Delays in drafting cause subsequent delays in market entry and revenue generation..

Rejection Risk
Manual quality control often overlooks minor inconsistencies across thousands of pages of documents. Mistakes can cause RTF[10] letters or lengthy rounds of HAQs[11], delaying approval by months.

The Solution - Autonomous Regulatory Intelligence & Generative Authoring

1. **Regulatory Horizon Scanning Agent** - an AI agent that continuously monitors global Health Authority publications (e.g., FDA Guidance, EMA Policy), filtering out noise to identify statutory changes relevant to your specific portfolio. It distinguishes critical legislative updates from routine competitor submissions. It can filter out distractions and generate concise impact assessment summaries, alerting regulatory intelligence teams only when relevant changes happen, helping to keep your submission strategy up-to-date without manual overload [26].

2. **Agentic Submission Authoring** - Going beyond simple drafting, an Agentic AI workflow iteratively creates, critiques, and refines sections of the CTD[12]. Like the “scientist-reviewer” loops proposed in recent research [81], one agent drafts the content based on statistical outputs (TLFs). In contrast, a second agent reviews it for logic and style, collaborating to produce a high-fidelity final draft. For instance, it can auto-draft a CSR[13] directly from statistical output (TLFs)[14] [27].

3. **Automated QC & Validation** - AI agents can review submission documents for internal consistency (e.g., ensuring numbers in the text match the tables) and formatting compliance. This “pre-validation” occurs within minutes, allowing for a “First Time Right” submission [26].

[10]RTF = Refuse to File

[11]HAQs = Health Authority Queries

[12]CTD = Common Technical Document

[13]CSR = Clinical Study Report

[14]TLFs = Tables, Listings, and Figures

The Strategic Value of AI - Faster Approval, Lower Risk

Speed to Market

Agentic Submission Authoring breaks the drafting bottleneck. By auto-generating CSRs and Module 2 summaries from statistical outputs, regulatory teams can cut document preparation time by 40-60%, speeding up submission readiness [28].

First-Cycle Approval

Automated QC & Validation Agents act as a tireless “pre-regulator.” By catching consistency errors and broken references that humans miss, these tools minimize rejection risks and reduce the volume of HAQs [29].

Cost & Resource Efficiency

Automating repetitive and labor-intensive parts of submission preparation—such as drafting standard text, formatting, and metadata tagging—reduces the human effort and enables regulatory staff to focus on high-value strategic tasks [30].

Scalability

Regulatory Horizon Scanning Agents decouple growth from headcount. They enable teams to monitor thousands of global regulatory changes without increasing staff, enabling scalable compliance across new markets [26].[26, 29].

Improved Accuracy & Consistency

AI Systems, especially those using machine learning and NLP, provide consistent, tireless review of dossiers—identifying inconsistencies, broken references, missing elements, or formatting issues that manual QC might overlook under time pressure [28]

The Encora Edge

AI-driven authoring is only as reliable as the data feeding it. We help Life Science leaders move beyond "black box" generation by engineering transparent, audit-ready data pipelines. Our expertise in Natural Language Processing (NLP) and content orchestration allows us to build submission engines that not only draft documents but trace every claim back to its source data, ensuring your accelerated submissions remain fully compliant and verifiable.

Discover our engineering capabilities at www.encora.com.

Part III - Manufacturing & Supply Chain

KPA 5. Manufacturing & Quality Control

The Challenge - Yield Variability and Production Inefficiency

Manufacturing—especially biologics, cell, and gene therapies—depends on tightly regulated living systems. Even minor deviations can lead to unpredictable yields, higher costs, and supply interruptions.

Bioreactor Variability
Cell culture performance is sensitive to environmental factors. Slight changes in pH, dissolved oxygen, or nutrient feed can significantly lower yield, with a single failed batch costing millions and worsening supply shortages.

Capacity Constraints
Manufacturing expansions require years and billions in capital. This forces manufacturers to optimize productivity with their current facilities.

Data Silos
Critical process data is often stored in historian databases, separate from quality, MES[15], and supply chain systems, which hinders end-to-end process optimization.

The Solution - Digital Twins & AI Process Control

Bioreactor Yield Optimization (Biologics)
I models can process real-time sensor data (pH, DO[16], biomass, feed rates) to create a continuously updated digital twin of the bioreactor. This enables the system to forecast batch trajectories and suggest real-time adjustments to maximize yield and consistency [31].

Predictive Maintenance
By analyzing vibration, acoustic, and performance data, AI models can predict equipment degradation before failure occurs. This allows maintenance during planned downtime, reducing disruptions and extending asset lifespan [32].

Automated Quality Control
Computer vision systems have been demonstrated in academic research to provide quick, precise, and consistent inspection of consumables and containers (e.g., vials, test tubes), surpassing manual inspection in repeatability and speed, and decreasing defect rates or waste [33].

[15]MES = Manufacturing Execution System

[16]DO = Dissolved Oxygen

The Strategic Value of AI – Maximizing Output and Asset Utilization

Yield Improvement Bioreactor Digital Twins drive “Golden Batch” consistency by adjusting process parameters in real time based on predictive yield trajectories. This allows manufacturers to reduce batch variability and maximize yield [31, 34].

Defect Reduction

Computer Vision Inspection outperforms the human eye in consistency. Implementing automated visual QC provides accurate, reproducible inspection of consumables, reducing defect rates and waste [33].

Asset Utilization

Predictive Maintenance Agents convert unplanned downtime into scheduled maintenance. By alerting operators to equipment degradation before failure, AI extends asset life and prevents costly production stoppages [32].

Reduced Experimental / Qualification Burden

Using digital twins for in silico DoE[17] can significantly lower the number of physical experiments needed to explore optimal process spaces, reducing time, material use, and the risk of failed runs [35].

Throughput Increase

AI-based scheduling and workforce deployment have demonstrated the ability to boost upstream throughput by 15% and downstream throughput by 30-60% [36].

Cost & Quality Benefits

Reduction in COGM and Waste / Defects - The same McKinsey analysis indicates that closing the yield/throughput gap could cut COGM[18] by nearly 10% at those plants.



[17]DoE = Design of Experiments

[18]COGM = Cost of Goods Manufactured

KPA 6. Supply Chain Management

The Challenge - Fragility, Wastage, and Disruption

The pharmaceutical supply chain is worldwide, fragmented, and notoriously fragile. It faces two main threats - external disruptions and internal inefficiencies related to temperature-sensitive products (cold chain).

323

Drug Shortages

Supply chain resilience is a matter of patient safety. In Q1 2024, there were 323 active drug shortages in the US, the highest number since 2001 [37]. While many shortages in generics are caused by economic factors, shortages of high-value biologics and complex therapies are often due to manufacturing deviations and cold-chain failures, presenting a distinct, solvable operational challenge.

50%

Cold Chain Wastage

Many vaccines and biologics require strict temperature control. Shockingly, up to 50% of vaccines are wasted worldwide due to temperature excursions and logistical failures [38]. The financial loss from these cold chain issues is estimated at $35 billion annually [44].

$11 Billion

Disruption Costs

Supply chain disruptions result in an average of $11 billion in annual losses for the healthcare industry [39].

The Solution - The Self-Driving Supply Chain

1. **Cognitive Cold Chain IoT[19] + AI-powered Monitoring & Control Tower -** Real-time temperature and location monitoring of pharma shipments (cold chain), combined with AI-based risk analysis and proactive alerts. SkyCell provides real-time shipment tracking, predictive insights, and automated alerts to the pharma supply chain community [40].

2. **Predictive Logistics, Demand Planning & Optimization via AI (AIoT + ML[20] / Optimization Models)** - IoT sensors on distribution centers and trucks can provide real-time data to AI/ML algorithms that optimize routing, inventory placement, and shipment schedules. This helps cut operational and transportation costs while keeping cold-chain integrity, supports proactive demand planning, and allows dynamic responses to supply chain disruptions [41].

3. **AI + Cold-Chain Automation** - AI-driven cold-chain logistics - combining sensors, predictive analytics, and digital twins - is increasingly used in pharmaceuticals and perishable goods to improve monitoring, reduce waste, and boost reliability [42].

4. **Sustainability, Efficiency & Resilience** - Real-time monitoring and AI orchestration can reduce product loss, enhance shipments, and strengthen supply-chain resilience, addressing both financial losses (~$35B worldwide from cold-chain waste) and environmental impact [43].

[19]IoT = Internet of Things

[20]ML = Machine Learning

The Strategic Value of AI - Resilience and Responsibility

Reduced Disruption Costs

AI Control Towers provide the visibility needed to act. By predicting logistical bottlenecks or weather disruptions days in advance, teams can reroute shipments proactively, reducing disruption-related costs by up to 80% [39].

Wastage Reduction

Cognitive Cold Chain monitoring safeguards inventory. Real-time intervention alerts prevent temperature excursions, directly addressing the $35 billion annual loss from cold-chain waste [44].

Sustainability

Reducing wastage also lowers the carbon footprint of the pharma supply chain. AI-optimized logistics cut down on unnecessary shipments and spoilage-related disposal.

Service Level Optimization

Predictive Demand Planning reduces the “Bullwhip Effect” by aligning production schedules with AI-forecasted demand, helping companies avoid stockouts and reduce working capital tied up in safety stock [41].

Strategic Differentiation & Competitive Edge

For a company capable of delivering a “self-driving supply chain”—that is, integrated predictive AI, real-time monitoring, and control tower orchestration—the combination of lower costs, increased reliability, and better sustainability provides a distinct competitive edge compared to traditional, reactive supply chain models.

The Encora Edge

Real-time quality control requires a 'Composable Enterprise' architecture. Our engineers specialize in building GxP-compliant data platforms that unify disparate factory-floor and supply chain data into a single, audit-ready source of truth, ensuring that 'Art of the Possible' AI agents have the high-fidelity data they need to act.

Part IV - Commercial & Medical Affairs

KPA 7. Commercialization

The Challenge - The “Share of Voice” Dead End

The traditional commercial model—relying on frequent sales rep visits and broad marketing—has become ineffective. HCPs are overwhelmed, and access is quickly shrinking.

- **Declining Access** - Access to physicians is at an all-time low. Only 44% of physicians are considered “accessible” to sales reps [6]. In specialized areas like oncology, 73% of oncologists limit interactions with reps [45].

- **Digital Fatigue** - The shift to digital during the pandemic has caused inbox overload. HCPs are flooded with generic emails, reducing their engagement [46]. Broad “spray and pray” tactics are producing fewer results [45].

- **High Acquisition Costs** - Dependence on costly field teams that often face barriers at the door leads to an unsustainable Cost-to-Serve [46].

The Solution - Hyper-Personalized Omnichannel Engagement

1. **Next-Best-Action (NBA) Agents** - AI can analyze an HCP's historical interactions, prescribing behaviors, and channel preferences to recommend the single best action for a rep or digital channel (e.g., “Dr. Smith prefers emails on Tuesday mornings; send the new cardiac safety data now”) [46].
2. **Generative Content Factory** - Instead of one-size-fits-all brochures, GenAI agents can create hyper-personalized content for micro-segments. They can generate modular emails, slide decks, and portal content tailored to a specific physician's scientific interests and patient demographic [46].
3. **Dynamic Targeting** - Moving beyond static “decile” targeting updates, AI can refresh customer segmentation in real-time based on triggers (e.g., a new guideline release, a change in patient volume, a competitor launch) [47].

The Strategic Value of AI - Precision and Efficiency

33% **Increased Engagement**
Generative Content Factories solve the “content crunch.” By tailoring messaging to specific micro-segments at scale, email open rates can increase by 33% compared to generic “spray and pray” broadcasts [46].

10% **Sales Uplift**
Next-Best-Action (NBA) Agents ensure every interaction counts. By guiding reps to the right channel and message for each HCP, AI drives a potential 10% sales uplift through more relevant interactions [47].

Resource Optimization
Dynamic Targeting ensures expensive field resources are not wasted on low-access HCPs. AI orchestrates the mix, deploying reps only for complex scientific exchange while “digital workers” handle routine engagement, lowering the overall Cost-to-Serve [46].

KPA 8. Medical Affairs

The Challenge - Strategic Value Diluted by Administration

MSLs[21] are the scientific backbone of pharmaceutical companies, critical for engaging KOLs[22]. However, their strategic value is often bottlenecked by administrative burdens.

Administrative Burden

MSLs are highly qualified scientific experts, yet they spend a significant portion of their time on non-value-added tasks - logging CRM[23] entries, scheduling, and manual reporting [48].

Insight Latency

MSLs gather critical insights from KOLs (e.g., concerns about a trial design, off-label observations), but this data often sits in free-text notes in a CRM platform. It can take months for these insights to be manually synthesized and reach headquarters to influence strategy [49].

Measurement Difficulty

67% of medical affairs professionals find it difficult to accurately measure MSL performance and impact, often relying on vanity metrics (number of visits) rather than value metrics such as Share of Scientific Voice (SoSV) or Key Opinion Leader (KOL) Sentiment Shift [50].

The Solution - The AI-Augmented MSL

Insight Synthesis Agent - This agent can use Natural Language Processing (NLP) to read and analyze thousands of free-text MSL notes. It identifies trending topics, sentiment shifts, and competitive intelligence in real time, turning “data exhaust” into strategic intelligence.

Automated Admin - “Virtual MSL Assistants” can handle routine tasks like scheduling, expense reporting, and drafting follow-up emails based on conversation context. This frees MSLs to focus on scientific exchange [48].

KOL Digital Twins - AI can analyze a KOL's public footprint-publications, tweets, speaking engagements, trial participation- to create a dynamic profile of their scientific interests. This allows MSLs to prepare for meetings with highly relevant, tailored scientific talking points.`



[21]MSL = Medical Science Liaison

[22]KOL = Key Opinion Leader

[23]CRM = Customer Relationship Management

The Strategic Value of AI - Strategic Agility

Time Savings

Virtual MSL Assistants remove the administrative burden. By automating CRM entry, scheduling, and expense reporting, AI returns 3-5 hours per week to MSLs, increasing their capacity for scientific exchange [48].

Real-Time Intelligence

Insight Synthesis Agents turn “data exhaust” into strategy. By using NLP to analyze thousands of free-text notes instantly, companies can detect competitive threats or safety signals in days rather than months [49].

High-Quality Engagement

KOL Digital Twins enable hyper-relevant preparation. MSLs armed with a complete, AI-generated view of a KOL’s recent research and interests can deliver deeper value during limited face-to-face time [51].



KPA 9. Clinical Trials - Phase 4 & Real-World Evidence

The Challenge - The Evidence Gap & Post Market Costs

Approval is not the finish line. Companies must often conduct Phase 4 or post-market studies to prove long-term safety or value. and fully capture how a drug is actually used. Traditional RCTs are often ill-suited for these post-market needs.

High cost and inefficiency of RCTs
Conventional RCTs24 have become resource-intensive, time-consuming, and complex - especially for rare diseases or therapies where populations are small or heterogeneous [52].

Generalizability gap
RCTs typically require strict inclusion/exclusion criteria, which may exclude patients with comorbidities or other real-world characteristics - meaning trial data may not predict how a drug performs across the broader, more diverse real-world patient populations [53].

Reimbursement and payer hurdles
Payers and HTA25 bodies(eq NICE, ICER, AHRQ) often require evidence of real-world effectiveness, long-term safety, cost-effectiveness, or value over standard of care; without such evidence, formulary access or value-based reimbursement may be constrained. This makes post-market evidence generation critically important [52].

The Solution - The RWE Generation Engine

Recent advances in RWD[26] collection and analytical methods can enable a more flexible, scalable way to generate RWE[27] across the product lifecycle -

1. Automated RWE Platforms - AI/analytic agents can ingest and harmonize diverse RWD sources - EHRs[28], claims databases, registries, and potentially even patient-generated data (e.g., wearables) - to build evidence bases outside traditional RCT infrastructure [54].

2. External / Synthetic Control Arms - For single-arm trials or situations where a new RCT is unfeasible (e.g., rare diseases), RWD can be used to construct external comparator arms - enabling benchmarking versus standard of care without recruiting a parallel control group [55].

3. Value-Based Care & Health-Economic Modeling - RWE can feed into budgetimpact and cost-effectiveness models for specific payer populations. Observational data reflecting real-world practice patterns, patient mix, resource use, and long-term outcomes can support value-based contracts, pricing negotiations, and reimbursement submissions. Many HTA bodies (e.g., NICE in the UK) already recommend RWD/ RWE to assess the applicability of interventions, long-term safety, outcomes in routine care, and economic impact [56].

[24]RCTs = Randomized Controlled Trials

[25]HTA = Health and Technology Assessment

[26]RWD = Real-World Data

[27]RWE = Real-World Evidence

[28]EHR = Electronic Health Record

The Strategic Value of AI - Lifecycle Value Maximization

Cost Efficiency

Automated RWE Platforms dramatically lower the cost of evidence generation. By using agents to ingest and harmonize disparate EHR and claims data, companies can generate post-market safety/efficacy evidence more efficiently than prospective RCTs [57].

Broader Generalizability

Since RWE draws from routine care in heterogeneous populations, it better reflects real-world patients, making outcomes more relevant to payers and real-world clinical practice [53].

Accelerated Access

External Control Arms (Synthetic Controls) accelerate the path to value. For rare diseases or single-arm trials, using AI to construct a comparator arm from real-world data allows companies to demonstrate comparative value without recruiting a parallel control group [55].

Lifecycle Maximization

Value-Based Modeling Agents support reimbursement defense. By continuously simulating cost-effectiveness based on real-world usage patterns, AI provides the dynamic evidence needed to sustain pricing and formulary position [56].



The Encora Edge

Real-World Evidence is often trapped in fragmented, messy datasets that defy standard analysis. Encora's data engineering teams specialize in unifying these disparate sources—from EHRs and claims data to wearable sensors—into a high-fidelity, interoperable data fabric. We engineer the secure, scalable platforms required to turn raw real-world data into regulator-grade evidence, enabling you to prove value and secure reimbursement faster

See how we accelerate data outcomes at www.encora.com.

Part V - Post-Market Surveillance & Patient Support

KPA 10. Pharmacovigilance

The Challenge - The Safety Data Tsunami

- **Volume Overload** - The FDA's FAERS[29] database receives over 2 million reports annually, and the agency recently moved to daily publication of AE data, underscoring that volume is increasing [59].

- **Cost Pressure** - Manual case processing is labor-intensive and repetitive, consuming the bulk of PV[30] department resources and diverting effort away from higher-value activities, such as risk management. This challenge is often cited as motivation for automation in modern PV operations [60].

- **Signal Noise** - With the surge in report volume (including many non-serious and low-priority cases), manually finding accurate safety signals becomes increasingly tricky. High volume contributes to "noise," making it harder to detect real issues in a timely fashion - a risk of human error and alert fatigue [61].

The Solution - Touchless Case Processing

Cognitive Case Intake AI agents

AI/ML (e.g., NLP) can ingest AE reports from varied sources (email, social media, callcenter logs, attachments), extract relevant entities (patient, drug, event), code them against standard terminologies (e.g., MedDRA), and classify seriousness/validity automatically [62].

Touchless Processing

For non-serious, high-volume cases (which typically constitute a large portion of total volume), the AI system can process end-to-end without human intervention and submit directly to the safety database; humans would only review complex, serious, or low-confidence cases. This model is one of the strategic advantages described by industry sources advocating AI/automation in PV [61].

Predictive SignalDetection AI

Beyond exhaustion of manual review, AI-based algorithms can monitor the safety database (FAERS or internal safety databases) in near-realtime, applying statistical or ML-driven anomaly detection across aggregated data to flag early safety signals more quickly than traditional datamining workflows. This is considered one of the key value propositions of advanced pharmacovigilance automation [61].

[29]FAERS = FDA Adverse Event Reporting System

[30]PV = Pharmacovigilance

The Strategic Value of AI - Safety and Scalability

Cost Reduction

Touchless Case Processing decouples volume from cost. By automating the end-to-end processing of non-serious cases, PV departments can cut case-processing costs by 40-60% [63].

Operational Scalability

Cognitive Intake Agents handle the “Safety Data Tsunami.” By standardizing unstructured intake from emails and calls automatically, PV teams can reduce case handling time by 40-50% [63].

Signal Precision

Predictive Signal Detection moves safety from reactive to proactive. By detecting statistical anomalies in real-time across aggregated data, AI helps identify genuine risks faster than manual data mining, enhancing patient safety [61].

Enhanced Compliance and Consistency

Touch less processing ensures uniform coding and reporting according to regulatory standards (e.g. MedDRA[31], ICHE2B)[32], lowering the risk of compliance findings, reducing manual errors, and freeing up safety physicians to focus on signal analysis and risk assessment rather than repetitive data entry [60].

[31]MedDRA = Medical Dictionary for Regulatory Activities

[32]A standard for electronic reporting of ADEs

KPA 11.
Patient Engagement

The Challenge - The Problem - The Adherence Gap

Developing a life-saving drug is only half the battle; patients must actually take it and stay compliant with dosing guidelines. Non-adherence is a massive, silent failure in the healthcare system.

Adherence Crisis

Approximately 40–50% of patients with chronic conditions do not take their medications as prescribed [64].

Human and Economic Cost

Medication non-adherence has been associated with an estimated 100,000–125,000 preventable deaths and up to $100–300 billion in avoidable healthcare costs annually in the U.S. [65].

Patient Isolation

Patients often feel unsupported between doctor visits. Side effects, complex regimens, or waning motivation can lead them to discontinue therapy without consulting their provider [66].

The Solution - AI Digital Companions & The “Patient Guardian” System

Personalized Nudge Agents

AI-powered mobile apps can act as “digital companions.” They can learn a patient’s behavior and personality. If a patient misses a dose, the AI selects the best intervention-whether a gentle reminder, an informative alert, or a prompt to connect with a nurse [67].

Risk Prediction (The “Patient Guardian”)

A persistent, multi-agent system can fuel a “Patient Engagement Virtuous Cycle.” A Risk Scoring Agent calculates real-time risk scores for dropout and preventable adverse drug events (ADEs). Explainable AI (XAI) flags why a patient is at risk (e.g., “Decreasing mobility + missed diary entry” [68].

24/7 Support Bots

Conversational AI can provide instant, compliant answers to patient questions (“Can I take this with food?”, “Is this side effect normal?”), reducing anxiety and preventing unnecessary discontinuation. [69].



The Strategic Value of AI-Better Outcomes, Higher Revenue

Adherence Boost

Personalized Nudge Agents drive behavioral change. By delivering the right reminder at the right time (based on individual patient patterns), AI-driven apps have demonstrated adherence improvements of up to ~67% in studies [70].[64].

Patient Retention

The “Patient Guardian” (Risk Scoring) prevents dropouts. By flagging patients with high-risk scores before they quit, nurse teams can intervene precisely, improving therapy retention [71].

Operational Efficiency

AI Prioritization optimizes support teams. Instead of calling every patient, AI directs nurse educators to focus solely on high-risk patients identified by the system, maximizing the impact of limited human resources [72].



KPA 12.
Regulatory Affairs

The Challenge - The Maintenance Marathon

Once a product is on the market, the regulatory burden shifts to RLM[33]. Manufacturing changes, label updates, and annual reports create a constant stream of low-level, manual but critical work [73].

Variation Management

A single manufacturing change (e.g., changing a raw material supplier) might require filing "variations" in 100+ countries, each with different forms and local requirements. [74]

Regulatory Divergence

Global regulations constantly diverge. Tracking these changes manually across 80+ markets is impossible, leading to compliance gaps [75].

Labeling Inconsistency

Patients often feel unsupported between doctor visits. Side effects, complex regimens, or waning motivation can lead them to discontinue therapy without consulting their provider [66].

The Solution - Automated Lifecycle Management

RIM[35] Bots

RPA[36] bots, supervised by AI, can auto-populate variation packages for dozens of markets simultaneously within the RIM system [77].

Labeling Harmonization Agent

An AI can compare the CDS against local labels in every country (translating where necessary). It highlights discrepancies (e.g., "The safety warning in Japan does not match the new global standard"), ensuring global alignment.

Compliance Monitor

An AI agent can track global regulatory changes and automatically flags which products in the portfolio are affected, triggering the necessary workflows.

[33]RLM = Regulatory Lifecycle Management

[34]CDS = Core Data Sheet

[35]RIM = Regulatory Information Management

[36]RPA = Robotic Process Automation

The Strategic Value of AI - Agility and Risk Mitigation

Reduced Overhead

RIM Bots automate the “Maintenance Marathon.” By auto-populating variation packages for dozens of markets simultaneously, AI reduces the manual labor required for routine lifecycle management updates [78].

Risk Mitigation

Labeling Harmonization Agents prevent compliance gaps. By instantly comparing local labels against the Global CDS across 80+ countries, AI identifies discrepancies that human review might miss, reducing liability risks [79].

Supply Chain Agility

Compliance Monitor Agents speed up global rollouts. By accelerating regulatory approval of manufacturing changes (e.g., new suppliers) across all markets, AI enables the supply chain to achieve faster cost savings and resilience improvements [74].

The Encora Edge

Maintaining global compliance requires more than just tracking rules; it requires an intelligent, connected ecosystem. Encora leverages deep expertise in cloud modernization and robotic process automation (RPA) to transform static regulatory tracking into dynamic, automated workflows.
We help you engineer a "self-correcting" compliance engine that scales effortlessly across new markets without requiring a linear increase in headcount.

Learn more about our digital engineering solutions at www.encora.com.

Conclusion - From the “Art of the Possible” to the Reality of Execution

We have now traversed the whole landscape of the Art of the Possible. We have seen the evidence: drug discovery timelines compressed by 50%, pharmacovigilance costs slashed by 60%, and manufacturing yields optimized in real time. These are not theoretical benchmarks - they are the new operational standards competitors are already racing to achieve.

The question is no longer if AI will transform your value chain, but how quickly you can harness it before the gap becomes unbridgeable.

The Execution Gap - Why Pilots Fail

The industry is littered with stalled initiatives - “random acts of digital” that dazzle in the lab but disintegrate at the enterprise level. Organizations often fail not because they lack vision, but because they lack a cohesive **AI Strategy and Roadmap.** They attempt to layer advanced AI onto rigid, legacy infrastructures, resulting in friction rather than flow.

Whether you are starting from zero or looking to rescue a stalled transformation, the path out of “pilot purgatory” requires a fundamental shift in approach.

Your Action Plan - Building the Composable Enterprise

To move from isolated experiments to systemic value, you must stop buying “tools” and start engineering an ecosystem.

Align AI to Strategic “North Stars”

Stop asking where AI can be used; ask where it must be used.

The Shift

Don't fund AI projects; fund business outcomes.

The Action

Identify the 2-3 non-negotiable constraints choking your growth (e.g., “Shorten Phase III enrollment by 4 months” or “Eliminate 80% of manual regulatory filing errors”). If an AI initiative does not directly attack these metrics, pause it.

2. Architect for Agility - The Composable Core

Monolithic, “black box” platforms are the enemy of speed. The future belongs to the **Composable Enterprise** - an architecture where specialized AI agents (for molecular design, clinical recruitment, or safety signal detection) can be swapped, upgraded, and connected seamlessly.

The Shift - From rigid legacy systems to flexible components, including agents and data products.

The Action - Break down data silos. For example, ensure your R&D data foundation can “speak” to your Commercial engines, creating a feedback loop where market insights inform the next generation of drug discovery.



3. Accelerate with Engineering Rigor

Understanding the biology is your core competence; engineering the digital fabric that powers it is a discipline entirely different from it. Building a secure, compliant, and scalable AI infrastructure is not a side project - it is an engineering mandate.



The Executive Reality Check: Are You Ready? Before launching your next pilot, ask your team:

The Data Readiness Question:
“Is our current data infrastructure 'AI-Ready,' or are our data scientists still spending 80% of their time on manual data cleaning and 'janitor work'?”

The Compliance Question:
“How will we embed GxP and GDPR compliance directly into our AI code to ensure every automated decision is traceable and audit-ready?”

The Scalability Challenge:
“Can our legacy architecture support 'Agentic AI' orchestration, or will our AI initiatives remain trapped in isolated, non-scalable pilots?”

The Workforce Readiness Question:
“Is our culture ‘AI-Fluent,’ or is it paralyzed by ‘Black Box’ anxiety? Beyond hiring data scientists, do we have a Learning & Development roadmap to upskill domain experts - biologists, clinicians, and quality officers - to collaborate effectively with agentic workflows?”?

The Strategic Alignment Question:
“Are we just ‘doing digital,’ or are we driving value? Have we applied a Balanced Scorecard to ensure every AI pilot is explicitly linked to your strategic ‘North Star’ objective (e.g., reducing patient attrition) with defined KPIs before a single line of code is written?”

Encora: Your Partner in Orchestration and Engineering

Moving from a pilot to an enterprise-wide AI solution requires more than a model; it requires an engineering DNA. Encora provides the technical rigor to transform ad-hoc processes into validated, scalable workflows.

Our Proven Impact:

Speed
55% faster product development cycles for global leaders.

Scale
Management of complex migrations (e.g., 5.5M+ accounts/250k SKUs) with zero downtime.

Compliance
Deep expertise in GxP, HIPAA, and GDPR-compliant platform engineering.

Interoperability
Leaders in unifying fragmented EMR/EHR, Claims, and RWE data into AI-enabled data fabrics.

Your Next Step: Stop Exploring, Start Engineering

The tools to rewrite the future of human health are ready. The only variable remaining is the will to deploy them. Do not commit to a multi-year transformation without a proof of value.

Request an AI Strategy Session

In a focused executive workshop, we will help you:

Map your "North Star"
Identify the business outcomes that you must achieve where AI can have the best impact.

Demonstrate
accelerate a specific use case (e.g., Clinical Data Cleaning or PV Intake).

Outline a 6-week "Proof of Impact"
roadmap.

Don't just explore AI. Engineer it

Encora is a global digital engineering leader with 9,500+ experts across 40+ offices. We are the preferred innovation partner for companies looking to move at the speed of human need.

About Encora

Encora is a leading provider of Agentic-orchestration and AI-first software engineering solutions to some of the world's most innovative startups, rapidly scaling unicorns and established Fortune 1000 companies. Headquartered in Silicon Valley, with teams in four continents, Encora brings the power of 9500+ engineers, Industry expertise and deep relationships with the world's leading Hyperscalers, Data Platforms and SaaS platforms, to deliver product acceleration, smart experiences and operational agility.

Contact us to schedule a "Cognitive Enterprise Readiness Audit" and bridge your execution gap today.

Schedule Your AI Strategy Session

Our Life Sciences AI Lead:
Marc Hollyoak, AI Practice Leader, LinkedIn

Our Life Sciences Industry Lead:
Jodie Skyberg, SVP Healthcare & Life Sciences, LinkedIn

References

1. Deloitte (2024). Seize the Digital Momentum: Measuring the Return from Pharmaceutical Innovation 2023. https://www2.deloitte.com/us/en/pages/life-sciences-and-health-care/articles/measuring-return-from-pharmaceutical-innovation.html
2. Deloitte (2025) Global pharma R&D returns rise as one-off GLP-1 drugs help drive forecast growth. https://www.deloitte.com/uk/en/about/press-room/global-pharma-rd-returns-rise-as-one-glp-drugs-help-drive-forecast-growth.html
3. National Library of Medicine (2025) Trends, Charts, and Maps. https://clinicaltrials.gov/about-site/trends-charts
4. National Library of Medicine (2024) Post-approval changes in pharmaceuticals. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11043098
5. 360 Research Reports (2024) Pharmaceutical Compliance Software Market. https://www.360researchreports.com/market-reports/pharmaceutical-compliance-software-market-205658
6. ZS Associates (2024). AccessMonitor 2024: Finding the Mix in a Hybrid World. https://www.zs.com/insights/accessmonitor-2024
7. McKinsey & Company (2024) Generative AI in the pharmaceutical industry: Moving from hype to reality. https://www.mckinsey.com/industries/life-sciences/our-insights/generative-ai-in-the-pharmaceutical-industry-moving-from-hype-to-reality
8. World Courier (2025) When reliability is non-negotiable. https://www.worldcourier.com/insights/when-reliability-is-non-negotiable
9. MDPI (2023) Eroom's Law in Pharmaceutical R&D. https://www.mdpi.com/1999-4923/15/6/1673
10. Encora (2025) Multi-Omics Data Chaos: Building AI-Ready Foundations. https://www.encora.com/insights/multi-omics-data-chaos-building-ai-ready-foundations
11. Cornell University (2022) Generative AI for De Novo Drug Design. https://arxiv.org/abs/2201.09647
12. Coherent Solutions (2025) Artificial Intelligence in Pharmaceuticals and Biotechnology: Current Trends and Innovations. https://www.coherentsolutions.com/insights/artificial-intelligence-in-pharmaceuticals-and-biotechnology-current-trends-and-innovations
13. National Library of Medicine (2019) Poor Translatability of Biomedical Research Using Animals — A Narrative Review. https://pubmed.ncbi.nlm.nih.gov/
14. Fierce Biotech (2025) FDA issues draft guidance to reduce primate testing for certain antibodies. https://www.fiercebiotech.com/biotech/fda-issues-draft-guidance-reduce-primate-testing-certain-antibodies
15. Ellipse (2025) Reducing the use of animals in toxicological research with data science and artificial intelligence. https://ellipse.prbb.org/reducing-the-use-of-animals-in-toxicological-research-with-data-science-and-artificial-intelligence/
16. 2 Minute Medicine (2025) Artificial intelligence accelerates drug discovery and reduces animal testing. https://www.2minutemedicine.com/artificial-intelligence-accelerates-drug-discovery-and-reduces-animal-testing/
17. FDA (2025) FDA Announces Plan to Phase Out Animal Testing Requirement for Monoclonal Antibodies and Other Drugs. https://www.fda.gov/news-events/press-announcements/fda-announces-plan-phase-out-animal-testing-requirement-monoclonal-antibodies-and-other-drugs
18. National Library of Medicine (2024) Clinical trial protocol amendments: cost and time. https://pubmed.ncbi.nlm.nih.gov/38438658/
19. ICON plc (2025) Controlling complexity: Regulator-ready protocol. https://www.iconplc.com/insights/blog/2025/04/09/controlling-complexity-regulator-ready-protocol
20. National Library of Medicine (2020) Recruitment and retention of participants in clinical trials. https://pmc.ncbi.nlm.nih.gov/articles/PMC7673977/

References

21. Tufts CSDD (2025) Quantifying the Value of a Day of Delay in Drug Development. https://csdd.tufts.edu/sites/default/files/2025-02/Aug2024%20Day%20of%20Delay%20White%20Paper%20Final.pdf
22. National Library of Medicine (2018) Cycle times in clinical trial data management. https://pubmed.ncbi.nlm.nih.gov/29714600/
23. McKinsey & Company (2025) Unlocking peak operational performance in clinical development with artificial intelligence. https://www.mckinsey.com/industries/life-sciences/our-insights/unlocking-peak-operational-performance-in-clinical-development-with-artificial-intelligence
24. Applied Clinical Trials (2025) New Insights On the Impact of AI-Enabled Solutions. https://www.appliedclinicaltrialsonline.com/view/new-insights-on-the-impact-of-ai-enabled-solutions
25. McKinsey & Company (2025) With Gen AI, Merck and McKinsey transform clinical authoring. https://www.mckinsey.com/about-us/new-at-mckinsey-blog/with-gen-ai-merck-and-mckinsey-transform-clinical-authoring
26. National Library of Medicine (2025) AI in Regulatory Intelligence. https://pubmed.ncbi.nlm.nih.gov/39776314/
27. Aequor (2025) AI for Regulatory Medical Writing: Automating Submissions with Confidence. https://www.aequor.com/resources/ai-for-regulatory-medical-writing-automating-submissions-with-confidence/
28. LS Academy (2025) How AI is Transforming Regulatory Affairs. https://lsacademy.com/en/how-ai-is-transforming-regulatory-affairs
29. DDReg Pharma (2025) AI-Powered Regulatory Submissions: A New Era for IND, NDA, BLA Documentation. https://resource.ddregpharma.com/blogs/ai-powered-regulatory-submissions-a-new-era-for-ind-nda-bla-documentation/
30. PwC (2025) AI-powered Regulatory Affairs. https://www.pwc.ch/en/insights/tax/pharma-life-sciences/ai-powered-reg-affairs.html
31. Pharma Focus Europe (2025) Digital Twins in Pharma. https://www.pharmafocuseurope.com/articles/digital-twins-in-pharma
32. MDPI (2025) Predictive Maintenance in Pharmaceutical Manufacturing. https://www.mdpi.com/2227-7390/13/6/981
33. Science Direct (2024) Computer vision for quality control in pharmaceutical manufacturing. https://www.sciencedirect.com/science/article/pii/S0957417424017597
34. National Library of Medicine (2025) Yield Optimization in Biopharma. https://pmc.ncbi.nlm.nih.gov/articles/PMC12516570
35. MDPI (2021) In Silico Design of Experiments. https://www.mdpi.com/2227-9717/9/7/1109
36. McKinsey & Company (2025) Human-machine harmonization to upgrade biopharma production. https://www.mckinsey.com/capabilities/operations/our-insights/human-machine-harmonization-to-upgrade-biopharma-production
37. Art of Procurement (2024) Symptoms of Disruption in the Pharmaceutical Supply Chain. https://artofprocurement.com/blog/supply-symptoms-of-disruption-in-the-pharmaceutical-supply-chain
38. TempControl (2025) How Vaccine Cold Chain Analysis Reduces Waste and Safeguards Potency in 2025. https://www.tempcontrolpack.com/knowledge/how-vaccine-cold-chain-analysis-reduces-waste-and-safeguards-potency-in-2025/
39. Express Pharma (2025) New data shows that targeted investment is reducing disruption in healthcare supply chains. https://www.expresspharma.in/new-data-shows-that-targeted-investment-is-reducing-disruption-in-healthcare-supply-chains/
40. Microsoft News (2025) SkyCell and Microsoft announce collaboration to bring Copilot into pharma supply chains. https://news.microsoft.com/de-ch/2025/04/07/skycell-and-microsoft-announce-collaboration-to-bring-copilot-into-pharma-supply-chains

References

41. MDPI (2025) AIoT and Optimization in Pharma Logistics. https://www.mdpi.com/2673-7590/5/1/1
42. Business Insider (2025) AI for cold chain operations: Safety algorithms, agents, and digital twins. https://www.businessinsider.com/ai-for-cold-chain-operations-safety-algorithms-agents-digital-twins-2025-7
43. Pharma Times (2025) SkyCell and Microsoft partner to improve pharma supply chains. https://pharmatimes.com/news/skycell-and-microsoft-partner-to-improve-pharma-supply-chains
44. IQVIA (2019). Strengthening the Pharmaceutical Supply Chain. https://www.iqvia.com Corex
45. PharmExec (2025) More Than Half US Physicians Place Moderate-to-Severe Restrictions on Pharma Sales Reps. https://www.pharmexec.com/view/more-half-us-physicians-place-moderate-severe-restrictions-pharma-sales-reps
46. IQVIA (2025) Reaching Healthcare Professionals in 2025. https://www.iqvia.com/locations/united-states/blogs/2025/09/reaching-healthcare-professionals-in-2025
47. Amra & Elma (2025) Marketing Personalization ROI Statistics 2025. https://www.amraandelma.com/marketing-personalization-roi-statistics/
48. Medium (2025) AI in Pharma: From Theory to Practice in Medical Affairs. https://medium.com/@andrewburak/ai-in-pharma-from-theory-to-practice-in-medical-affairs-09f531d98075
49. The MSL Journal (2025) The Impact of AI on Medical Affairs. https://themsljournal.com/article/the-impact-of-ai-on-medical-affairs/
50. National Library of Medicine (2025) Measuring MSL Performance. https://pmc.ncbi.nlm.nih.gov/articles/PMC12030051/
51. Bain & Company (2025) How Medical Affairs Can Break through the Noise in Pharma. https://www.bain.com/insights/how-medical-affairs-can-break-through-the-noise-in-pharma/
52. Office of Health Economics (2018) RWE for Coverage Decisions: Opportunities and Challenges. https://www.ohe.org/wp-content/uploads/2018/04/ICER-RWE-for-Coverage-Decisions-Opportunities-and-Challenges_0.pdf
53. National Library of Medicine (2024) Real-world data and evidence in drug development. https://pmc.ncbi.nlm.nih.gov/articles/PMC11267629/
54. FDA (2025) Real-World Evidence. https://www.fda.gov/science-research/science-and-research-special-topics/real-world-evidence
55. National Library of Medicine (2024) External Control Arms in Clinical Trials. https://pubmed.ncbi.nlm.nih.gov/39092896/
56. NICE (2025) Real-world evidence framework. https://www.nice.org.uk/corporate/ecd9/resources/nice-realworld-evidence-framework-pdf-1124020816837
57. BMJ Informatics (2025) Efficiency of RWE studies. https://informatics.bmj.com/content/22/3/368
58. National Library of Medicine (2024) RWE for Rare Diseases. https://pubmed.ncbi.nlm.nih.gov/38475874
59. Practical Neurology (2025) FDA Updates Adverse Drug Events Reporting Schedule. https://practicalneurology.com/news/fda-updates-adverse-drug-events-reporting-schedule/2483321/
60. WinWire (2025) Pharmacovigilance Automation. https://www.winwire.com/blog/pharmacovigilance-automation/
61. PharmExec (2025) Five Steps for Automating the Pharmacovigilance Process. https://www.pharmexec.com/view/five-steps-for-automating-the-pharmacovigilance-process
62. Vitrana (2025) Automating Case Intake in Pharmacovigilance. https://www.vitrana.com/automating-case-intake-in-pharmacovigilance-tools-process-roi
63. WinWire (2025) Life Sciences Solutions: PV Process Automation. https://www.winwire.com/lifesciences-solutions/pharmacovigilance-process-automation

References

64. National Library of Medicine (2018) Medication Adherence. https://pubmed.ncbi.nlm.nih.gov/30005722/
65. American Heart Association (2025) Medication Adherence - Taking Your Meds as Directed. https://www.heart.org/en/health-topics/consumer-healthcare/medication-information/medication-adherence-taking-your-meds-as-directed
66. Springer (2025) Barriers to adherence. https://link.springer.com/article/10.1186/1472-6963-11-326
67. Cornell University (2017) Mobile apps for medication adherence. https://arxiv.org/abs/1708.02924
68. Cornell University (2018) Explainable AI for Risk Prediction. https://arxiv.org/abs/1811.12234
69. Cornell University (2020) Conversational AI for Patient Support. https://arxiv.org/abs/2004.11479
70. Abbott (2025) Role of AI in Adherence. https://acarepro.abbott.com/articles/general-topics/role-of-ai-in-adherence/
71. Fierce Pharma (2025) AI for Medication Adherence: Friend or Foe? https://www.fiercepharma.com/sponsored/ai-medication-adherence-friend-or-foe
72. Emerj (2025) Artificial Intelligence at Cencora. https://emerj.com/artificial-intelligence-at-cencora/
73. Informa (2025) Future Global Pharmaceutical Regulatory Affairs Industry. https://turtlmedia.informa.com/story/future-global-pharmaceutical-regulatory-affairs-industry/page/6/1
74. Veeva Systems (2025) Connecting Quality and Regulatory for Data-Driven Change Control. https://www.veeva.com/blog/connecting-quality-and-regulatory-for-data-driven-change-control/
75. Freyr Solutions (2025) From Risk to Resilience: Pharma's Regulatory Playbook for 2025. https://www.freyrsolutions.com/blog/from-risk-to-resilience-pharmas-regulatory-playbook-for-2025
76. PharmaRegulatory (2025) Regulatory Lifecycle Management (RLM). https://www.pharmaregulatory.in/regulatory-lifecycle-management-rlm-scope-roles-and-definitions-for-global-pharma
77. ArisGlobal (2025) LifeSphere Regulatory RIM. https://www.arisglobal.com/lifesphere/regulatory/rim
78. Veeva Systems (2025) Growing Regulatory Strategic Value. https://www.industries.veeva.com/hubfs/us-lshc-growing-regulatory-strategic-value.pdf
79. PharmaRegulatory (2025) Lifecycle Change Tracking in RIM. https://www.pharmaregulatory.in/lifecycle-change-tracking-in-rim-dashboards-kpis-and-audit-readiness-for-global-dossiers
80. Scannell, J.W., Blanckley, A., Boldon, H., Warrington, B. (2012) Diagnosing the decline in pharmaceutical R&D efficiency. Nature Reviews Drug Discovery, 11(3), 191–200. https://www.nature.com/articles/nrd3681
81. Ng, Andrew (2025) Stanford Agentic Reviewer. https://paperreview.ai/tech-overview
82. Encora (2025). Encora Expands Enterprise Business Capabilities through a Strategic Acquisition from DMI. [Press release] 6 February. https://www.encora.com/en-US/news/encora-expands-enterprise-business-capabilities-through-a-strategic-acquisition-from-dmi
83. Encora (n.d.). Digital Product & Software Engineering Provider. https://www.encora.com/
84. Encora (n.d.). AWS Transformation Drives 70% Cost Savings for Pharmaceutical Giant. https://www.encora.com/our-work/aws-transformation-drives-70-cost-savings

encora

Visit us at www.encora.com